We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Clinical Lab Services Market to Reach USD 327 Billion by 2025

By LabMedica International staff writers
Posted on 17 Jul 2017
Print article
The global clinical laboratory services market is expected to reach USD 327 billion by 2025, driven by the improvement and implementation of informatics and automated data management solutions to perform seamless operations. The competition among medical device manufacturers for the development of clinical chemistry analyzers that can provide rapid results is also expected to aid the market growth. However, sample preparation and running it through experimental protocols with enhanced productivity still remains a challenge for labs.

These are the latest findings of Grand View Research, Inc. (San Francisco, CA, USA), a market research and consulting company.

In 2016, clinical chemistry services held the largest market share due to the presence of large number of body fluid-based screening solutions. Moreover, the segment caters to a large number of specialty including liver function tests, renal function tests, along with determination of different physiological substances.

Presently, growing concern over cost control, increasing the pace of R&D for new products, and demand for improvement in quality control parameters are some of the factors exerting pressure on lab personnel. Additionally, there has been continuous progress in a number of compounds screened in clinical settings, thus further demanding development in this field. The market players are making continuous efforts to address these challenges in different ways. For instance, vendors are adopting 384-well plates instead of 96-well plates in order to reduce reagent costs and the amount of time required for performing assays.

The emergence of tests that require smaller sample size and easy collection of the sample from patients is anticipated to boost R&D, thereby leading to potential growth prospects. Based on the current level of tests and application, medical microbiology & cytology is expected to record the fastest growth. The ability to provide better testing services at a comparatively lower rate is anticipated to increase the adoption of services by stand-alone laboratories, thereby fueling the market growth.

North America remains the market leader owing to technological advancements and high awareness of medical standards in the region, followed by Europe. However, the regions of Asia and Latin America are expected to witness rapid growth due to growing awareness, increased government initiatives, and favorable regulatory policies.

Related Links:
Grand View Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more